U.S. markets closed

Amarin Corporation plc (AMRN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.6000+0.1200 (+2.68%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close4.4800
Bid4.6000 x 29200
Ask4.6200 x 3000
Day's Range4.4600 - 4.6800
52 Week Range3.3600 - 26.1200
Avg. Volume9,490,406
Market Cap1.789B
Beta (5Y Monthly)2.96
PE Ratio (TTM)N/A
EPS (TTM)-0.0440
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.09
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Amarin to Present at Piper Sandler’s 32nd Annual Healthcare Conference (Virtual)

    Amarin to Present at Piper Sandler’s 32nd Annual Healthcare Conference (Virtual)

    DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to participate in a Fireside Chat at the Piper Sandler’s 32nd Annual Healthcare Conference (Virtual) taking place from December 1 - December 3, 2020. Mr. Thero’s presentation is scheduled to take place on Wednesday, December 2, 2020 at 10:00 am Eastern time. A live audio webcast of the presentations will be available at: http://www.amarincorp.com, and will be accessible at the same link for 30 days.About AmarinAmarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. Amarin’s lead product, VASCEPA® (icosapent ethyl), is available by prescription in the United States, Canada, Lebanon and the United Arab Emirates. VASCEPA is not yet approved and available in any other countries. Amarin, on its own or together with its commercial partners in select geographies, is pursuing additional regulatory approvals for VASCEPA in China, Europe and the Middle East. For more information about Amarin, visit www.amarincorp.com.Availability of Other Information About AmarinInvestors and others should note that Amarin communicates with its investors and the public using the company website (http://www.amarincorp.com/), the investor relations website (http://investor.amarincorp.com/), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.Amarin Contact InformationInvestor Inquiries: Investor Relations Amarin Corporation plc In U.S.: +1 (908) 719-1315 IR@amarincorp.com (investor inquiries)Solebury Trout amarinir@troutgroup.comMedia Inquiries: Communications Amarin Corporation plc In U.S.: +1 (908) 892-2028 PR@amarincorp.com (media inquiries)

  • Amarin vs. the Generics: Who Will Win?
    Motley Fool

    Amarin vs. the Generics: Who Will Win?

    After Amarin lost its patent rights in the U.S., the stock crashed overnight. Investors might want to stay optimistic.

  • Benzinga

    ROCE Insights For Amarin Corp

    During Q3, Amarin Corp (NASDAQ: AMRN) brought in sales totaling $156.50 million. However, earnings decreased 266.99%, resulting in a loss of $6.94 million. In Q2, Amarin Corp earned $4.16 million and total sales reached $135.32 million.What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q3, Amarin Corp posted an ROCE of -0.01%.Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.View more earnings on AMRNReturn on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.For Amarin Corp, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.Q3 Earnings Insight Amarin Corp reported Q3 earnings per share at $-0.02/share, which did not meet analyst predictions of $0.01/share.See more from Benzinga * Click here for options trades from Benzinga * Understanding Putnam Premier Income's Ex-Dividend Date * Ex-Dividend Date Insight: ACCO Brands(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.